ADA HbA1c guidelines 2014 established evidence-based glycaemic targets that continue to shape diabetes care internationally. Published as part of the American Diabetes Association's annual Standards of Medical Care in Diabetes, the 2014 update recommended an HbA1c target of less than 7.0% (53 mmol/mol) for most non-pregnant adults, whilst formally endorsing individualised goal-setting based on patient complexity. This article examines those recommendations in detail, compares them with current NICE guidance for UK practice, explores targets for specific patient groups, and outlines how guidelines have evolved in the decade since.

What the 2014 ADA HbA1c Guidelines Recommended

The 2014 ADA guidelines recommended an HbA1c target of less than 7.0% (53 mmol/mol) for most non-pregnant adults, with individualised targets between 6.5% and 8.0% based on hypoglycaemia risk, comorbidities, and life expectancy.

The American Diabetes Association (ADA) published its Standards of Medical Care in Diabetes—2014 as part of its annual guidance update, providing clinicians with evidence-based recommendations for the management of type 1 and type 2 diabetes. Central to these guidelines was the use of glycated haemoglobin (HbA1c) as the primary measure of long-term glycaemic control, reflecting average blood glucose levels over approximately two to three months.

The 2014 ADA guidelines recommended a general HbA1c target of less than 7.0% (53 mmol/mol) for most non-pregnant adults with diabetes. This threshold was supported by evidence from landmark trials — including the DCCT (Diabetes Control and Complications Trial) and UKPDS (UK Prospective Diabetes Study) — demonstrating that tighter glycaemic control significantly reduces the risk of microvascular complications such as diabetic nephropathy, retinopathy, and neuropathy.

Importantly, the 2014 guidance also acknowledged that a one-size-fits-all approach was inappropriate. The ADA explicitly recommended that targets be individualised based on factors including:

• Duration of diabetes

• Age and life expectancy

• Presence of comorbidities

• Risk of hypoglycaemia

• Patient preferences and engagement

For patients with a history of severe hypoglycaemia, limited life expectancy, or advanced complications, the ADA suggested a more relaxed target of less than 8.0% (64 mmol/mol). Conversely, a stricter target of less than 6.5% (48 mmol/mol) was considered appropriate for selected individuals — particularly those with short disease duration, long life expectancy, and no significant cardiovascular disease — provided it could be achieved safely without undue hypoglycaemia burden.

A note on HbA1c reliability: HbA1c may give misleading results in conditions that affect red blood cell turnover or haemoglobin structure, including haemoglobinopathies (such as sickle cell trait), haemolytic anaemia, iron deficiency anaemia, and during pregnancy. In these circumstances, alternative measures of glycaemic control — such as fructosamine, or continuous glucose monitoring (CGM) with time-in-range (TIR) data — should be considered alongside or instead of HbA1c.

HbA1c Targets: Comparing ADA and NICE Guidance

NICE NG28 recommends 48 mmol/mol (6.5%) for adults on lifestyle or non-hypoglycaemic therapy and 53 mmol/mol (7.0%) if hypoglycaemia risk exists, broadly aligning with the ADA 2014 standard target.

Whilst the ADA guidelines are produced in the United States, they carry significant international influence and are frequently referenced alongside UK-specific guidance from the National Institute for Health and Care Excellence (NICE). Understanding the similarities and differences between these two frameworks is valuable for UK clinicians and patients alike.

NICE guidance for type 2 diabetes (NG28, updated 2022) recommends an HbA1c target of 48 mmol/mol (6.5%) for adults managed by lifestyle intervention alone or a single non-hypoglycaemia-inducing drug. If the patient is on a drug associated with hypoglycaemia risk — such as a sulphonylurea or insulin — NICE recommends a target of 53 mmol/mol (7.0%). This broadly aligns with the ADA's 2014 general target of less than 7.0%, though the framing differs slightly.

For type 1 diabetes, NICE (NG17) recommends an HbA1c target of 48 mmol/mol (6.5%) or lower where achievable without problematic hypoglycaemia, which is somewhat more ambitious than the ADA's standard 7.0% threshold. Both organisations, however, converge on the principle that lower is not always better, particularly when hypoglycaemia risk is elevated.

A key practical difference lies in unit expression: the ADA uses percentage values (NGSP), whilst UK practice uses mmol/mol (IFCC). Clinicians and patients should be aware of this distinction to avoid confusion when interpreting international literature. The approximate conversions are:

• 6.5% ≈ 48 mmol/mol

• 7.0% ≈ 53 mmol/mol

• 8.0% ≈ 64 mmol/mol

Despite these nuances, both the ADA and NICE share a fundamentally patient-centred philosophy, emphasising shared decision-making and individualised target-setting.

Key references: NICE NG28 (Type 2 diabetes in adults: management, 2022 update); NICE NG17 (Type 1 diabetes in adults: diagnosis and management).

Individualising HbA1c Goals for Different Patient Groups

Targets should be relaxed for older or frail adults, tightened to 48 mmol/mol or below for pregnancy, and carefully balanced against hypoglycaemia risk in those with established cardiovascular disease.

One of the most clinically significant contributions of the 2014 ADA guidelines was the formalisation of individualised glycaemic targets, moving away from a uniform approach towards a framework that accounts for patient complexity. This principle remains central to contemporary diabetes management in both US and UK practice.

Older adults Both the ADA and clinical expert consensus recognise that aggressive glycaemic control in older adults may carry more risk than benefit. It is important to note that NICE does not specify fixed numeric HbA1c bands for older adults; rather, NICE (NG28) emphasises individualisation based on frailty, comorbidity, and hypoglycaemia risk. ADA guidance and expert consensus have suggested that a relaxed target — broadly in the region of 58–64 mmol/mol (7.5–8.0%) — may be appropriate for elderly patients with multiple comorbidities, cognitive impairment, or frailty, but this should be agreed on an individual basis with the patient and their care team. The primary concern in this group is hypoglycaemia, which can precipitate falls, cardiac events, and hospital admission.

Pregnancy For women with pre-existing diabetes who are planning a pregnancy or are pregnant, targets are considerably tighter. NICE (NG3: Diabetes in pregnancy) recommends that women aim for an HbA1c of 48 mmol/mol (6.5%) or below before conception and during pregnancy where safely achievable, given the association between poor glycaemic control and adverse foetal outcomes including congenital malformations and macrosomia. Women should be advised not to attempt conception if their HbA1c is above 86 mmol/mol (10%), owing to the substantially increased risk of adverse outcomes. High-dose folic acid (5 mg daily) is recommended from pre-conception until 12 weeks of gestation. It should also be noted that HbA1c is not a reliable measure of glycaemic control during pregnancy due to increased red cell turnover; CGM and self-monitoring of blood glucose are preferred during this period.

Children and young people NICE (NG18: Diabetes (type 1 and type 2) in children and young people) recommends an HbA1c target of 48 mmol/mol (6.5%) for children and young people with type 1 diabetes, though this must be balanced against the psychological burden of intensive management and the potential developmental impact of hypoglycaemia on the growing brain.

Established cardiovascular disease or history of severe hypoglycaemia Patients with established cardiovascular disease or a history of severe hypoglycaemia warrant particular attention. Evidence from the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes) demonstrated that intensive glucose lowering in high-risk patients was associated with increased mortality, reinforcing the importance of cautious, individualised target-setting. The 2014 ADA guidelines were among the first to formally incorporate this evidence into a tiered recommendations framework.

Key references: NICE NG3 (Diabetes in pregnancy); NICE NG18 (Diabetes in children and young people); ACCORD trial (Gerstein et al., NEJM 2008); ADA Standards of Medical Care in Diabetes—2014.

How Guidelines Have Evolved Since 2014

Since 2014, SGLT-2 inhibitors and GLP-1 receptor agonists with proven cardiovascular and renal benefits have reshaped prescribing priorities, and CGM with time-in-range is now a recognised complement to HbA1c monitoring.

Since the publication of the 2014 ADA Standards of Care, diabetes management guidelines have undergone substantial evolution, driven by a growing body of evidence from cardiovascular outcomes trials (CVOTs) and advances in pharmacotherapy.

Perhaps the most transformative development has been the emergence of SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin) and GLP-1 receptor agonists (e.g., semaglutide, liraglutide) as agents with proven cardiovascular and renal protective benefits, independent of their glucose-lowering effects. Trials such as EMPA-REG OUTCOME (Zinman et al., NEJM 2015) and LEADER (Marso et al., NEJM 2016) fundamentally changed prescribing priorities.

In UK practice, NICE (NG28, 2022) recommends SGLT-2 inhibitors for adults with type 2 diabetes who have established cardiovascular disease, heart failure, or chronic kidney disease, subject to eGFR thresholds and individual clinical criteria — and typically in addition to, or alongside, existing therapy. GLP-1 receptor agonists with proven cardiovascular benefit are similarly recommended within defined NICE criteria, for example in people with established cardiovascular disease where an SGLT-2 inhibitor is contraindicated or not tolerated. These recommendations are conditional on clinical eligibility and cost-effectiveness criteria; they are not applied universally regardless of baseline HbA1c or existing treatment. UK prescribers should refer to current NICE NG28 guidance and local formulary decisions for precise eligibility criteria.

The 2014 guidelines also predated widespread adoption of continuous glucose monitoring (CGM) and time-in-range (TIR) as complementary metrics to HbA1c. Current NICE guidance (NG17, NG18) now recommends CGM — including real-time CGM and flash glucose monitoring — for adults and children with type 1 diabetes, and for selected adults with type 2 diabetes on insulin. TIR — defined as the percentage of time glucose levels remain between 3.9 and 10.0 mmol/L — is now considered a meaningful additional outcome measure, particularly where HbA1c may be unreliable.

Furthermore, the language and philosophy of guidelines have shifted towards greater emphasis on weight management, remission of type 2 diabetes, and mental health. NICE's 2022 update explicitly addresses the possibility of type 2 diabetes remission through intensive lifestyle intervention or bariatric surgery — a concept largely absent from the 2014 ADA framework. These developments reflect a broader, more holistic understanding of diabetes care beyond glycaemic targets alone.

Key references: NICE NG28 (2022 update); NICE NG17; EMPA-REG OUTCOME trial; LEADER trial; MHRA Drug Safety Updates on SGLT-2 inhibitors.

Practical Implications for Diabetes Management in UK Practice

NICE recommends HbA1c monitoring every three to six months during treatment adjustment and every six months once stable, with targets reviewed alongside renal function, cardiovascular risk, and frailty.

For UK clinicians and patients, understanding the 2014 ADA HbA1c guidelines in context provides a useful historical reference point and highlights the enduring principles that continue to underpin modern diabetes care. Whilst UK practice is primarily guided by NICE and NHS frameworks, the ADA's contributions to evidence synthesis and target individualisation have had a lasting international influence.

In day-to-day practice, HbA1c remains a cornerstone of diabetes monitoring. NICE (NG28) recommends that HbA1c be measured every three to six months when treatment is being adjusted, and every six months once stable. Patients should be supported to understand their HbA1c result in the context of their individual target, rather than comparing themselves to a universal standard.

When to seek medical advice Patients and carers should contact their GP or diabetes team if they notice:

• HbA1c consistently above the agreed individual target despite adherence to treatment

• Frequent or severe hypoglycaemic episodes

• Symptoms suggesting poor glycaemic control (excessive thirst, fatigue, recurrent infections)

• Significant changes in weight, renal function, or cardiovascular status that may necessitate target revision

Urgent warning signs — seek emergency care immediately (call 999 or go to A&E) If a person with diabetes develops any of the following, this may indicate diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS) and requires emergency assessment without delay:

• High blood glucose with ketones in the blood or urine

• Nausea, vomiting, or abdominal pain

• Rapid or laboured breathing

• Drowsiness, confusion, or difficulty staying awake

• Fruity or acetone-like breath odour (in DKA) Do not wait for a routine appointment if these symptoms are present.

Medicines management and SGLT-2 inhibitor safety The MHRA has issued specific Drug Safety Updates regarding SGLT-2 inhibitors, including the risk of diabetic ketoacidosis (including euglycaemic DKA, where blood glucose may not be markedly elevated) and the need for dose adjustment or temporary discontinuation in certain situations. Patients taking SGLT-2 inhibitors should be advised to:

• Withhold the medication during acute illness, significant dehydration, or prolonged fasting (sick-day rules), and seek prompt medical advice

• Stop the medication at least three days before planned surgery or procedures requiring fasting, in line with MHRA and NICE guidance

• Be aware that ketone testing (blood or urine) is important if they feel unwell, even if blood glucose appears near-normal

UK prescribers should ensure that HbA1c targets are reviewed alongside the patient's full clinical picture, including renal function (eGFR thresholds affect drug choice and dosing), cardiovascular risk, and frailty status.

Reporting suspected side effects Patients, carers, and healthcare professionals are encouraged to report any suspected adverse drug reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. This applies to all medicines used in diabetes management, including insulin, SGLT-2 inhibitors, GLP-1 receptor agonists, and sulphonylureas.

Experiencing these side effects? Our pharmacists can help you navigate them →

Ultimately, the legacy of the 2014 ADA guidelines lies in their clear articulation of individualised, patient-centred care — a principle that remains as relevant today as it was a decade ago, and one that sits at the heart of both NICE guidance and good clinical practice across the UK.

Key references: NICE NG28 (monitoring intervals and medicines management); MHRA Drug Safety Update: SGLT-2 inhibitors — risk of diabetic ketoacidosis; NHS guidance on DKA and HHS.

Frequently Asked Questions